Basel, Switzerland – December 16, 2025 — BaseLaunch, a platform to launch, fund, and build early biotech ventures developing cutting-edge therapeutics, announced today Takeda has joined the Basel-based incubator, bringing the total number of leading pharma company partners to six.
Through its strategic investment in BaseLaunch, Takeda gains access to proven quality life sciences deal flow in central Europe and BaseLaunch`s company-building capabilities, while also providing expertise in biotech innovation and development of medicines. This will further help BaseLaunch develop its portfolio companies, which have collectively raised over $1 billion (USD).
”Our partnership with BaseLaunch strengthens our connection to European biotech innovation. By joining the investment board, we can help guide company creation and apply Takeda’s expertise in turning science into new therapies. We look forward to participating in BaseLaunch and advancing innovative medicines together.
Alison HandleyHead of the Center for External Innovation, Takeda
Six of the world’s leading pharmaceutical companies are currently partners of BaseLaunch. In addition to Takeda, these include AbbVie, Roche, Novo Nordisk, Johnson & Johnson and CSL. The venture fund Pureos Bioventures is also a partner. The commitment of these prominent partners demonstrates the continued success of the BaseLaunch setup that also deeply embeds the portfolio companies in the Basel area, a hotspot of European biopharma innovation.
